drugset / Trial / NCT05533203
Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 1
Unknown
24 enrolled
Shanghai Humantech Biotechnology Co. Ltd
Shanghai Changhai Hospital,The First Affiliated Hospital of Naval Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I clinical trial is to evaluate the safety of Prodencel (an autologous dendritic cell therapeutic tumor vaccine.) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Timeline
- Start
- 2022-08-08
- Primary completion
- 2023-08-30
- Completion
- 2024-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Prodencel | Vaccine | 5 cells | Subcutaneous |
| Subject | Prodencel | Vaccine | 10 cells | Subcutaneous |
| Subject | Prodencel | Vaccine | 15 cells | Subcutaneous |